172 related articles for article (PubMed ID: 25018868)
1. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.
Thanopoulou E; Thway K; Khabra K; Judson I
Clin Sarcoma Res; 2014; 4():5. PubMed ID: 25018868
[TBL] [Abstract][Full Text] [Related]
2. Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital.
Thanopoulou E; Aleksic A; Thway K; Khabra K; Judson I
Clin Sarcoma Res; 2015; 5():8. PubMed ID: 25810898
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
O'Cearbhaill R; Zhou Q; Iasonos A; Soslow RA; Leitao MM; Aghajanian C; Hensley ML
Gynecol Oncol; 2010 Mar; 116(3):424-9. PubMed ID: 19932916
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M;
Gynecol Oncol; 2021 Dec; 163(3):524-530. PubMed ID: 34625284
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
7. Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Shankar A; Roy S; Rath GK; Julka PK; Kamal VK; Malik A; Patil J; Jeyaraj PA; Mahajan MK
Asian Pac J Cancer Prev; 2015; 16(15):6359-64. PubMed ID: 26434843
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO).
Rubio MJ; Lecumberri MJ; Varela S; Alarcón J; Ortega ME; Gaba L; Espinós J; Calzas J; Barretina P; Ruiz I; Marquina G; Santaballa A
Gynecol Oncol Rep; 2020 Aug; 33():100594. PubMed ID: 32566719
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M;
Gynecol Oncol; 2021 Oct; 163(1):72-78. PubMed ID: 34412908
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
[TBL] [Abstract][Full Text] [Related]
11. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Shimoi T; Sagara Y; Hara F; Toyama T; Iwata H
Breast Cancer; 2020 May; 27(3):340-346. PubMed ID: 32043218
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors.
Lee JK; Im SA; Lee D; Kim JY; Lim Y; Lee E; Moon HG; Kim TY; Han SW; Oh DY; Lee SH; Han W; Kim DW; Kim TY; Noh DY
J Breast Cancer; 2013 Mar; 16(1):66-71. PubMed ID: 23593084
[TBL] [Abstract][Full Text] [Related]
13. Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
Reinert T; Debiasi M; Bines J; Barrios CH
Breast Cancer Res Treat; 2018 Apr; 168(2):457-465. PubMed ID: 29190006
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS).
Slomovitz BM; Taub MC; Huang M; Levenback C; Coleman RL
Gynecol Oncol Rep; 2019 Feb; 27():1-4. PubMed ID: 30519622
[TBL] [Abstract][Full Text] [Related]
15. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
16. Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment.
Sanfilippo R; Sbaraglia M; Fabbroni C; Croce S; Ray-Coquard I; Guermazi F; Paolini B; Blanc-Durand F; Lecesne A; Chiappa V; Dei Tos AP; Casali PG
Clin Cancer Res; 2023 Nov; 29(22):4679-4684. PubMed ID: 37699075
[TBL] [Abstract][Full Text] [Related]
17. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
Li JW; Zuo WJ; Ivanova D; Jia XQ; Lei L; Liu GY
Breast Cancer Res Treat; 2019 Jan; 173(2):407-415. PubMed ID: 30361875
[TBL] [Abstract][Full Text] [Related]
18. Clinical study of first-line endocrine therapy for type ER+/PR+ and ER+/PR- advanced breast cancer.
Zhang M; Yan M; Lv H; Niu L; Zeng H
Ann Palliat Med; 2021 Jan; 10(1):238-243. PubMed ID: 33545761
[TBL] [Abstract][Full Text] [Related]
19. [Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer].
Zhang MW; Lyu HM; Niu LM; Zeng HA; Yan M
Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):741-744. PubMed ID: 35280019
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
